DAX23.970 -1,0%ESt505.338 -0,3%Top 10 Crypto16,23 +2,0%Dow44.838 -0,1%Nas21.179 +0,3%Bitcoin101.817 +0,2%Euro1,1589 ±-0,0%Öl70,40 +2,9%Gold3.315 -0,7%

Intellia Therapeutics Aktie

Kaufen

Verkaufen

Handeln Handeln

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

11,38 EUR -0,18 EUR -1,51 %

28.07.2025

BMN

13,37 USD +0,26 USD +1,98 %

nachbörslich28.07.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Smartphone

Marktkap.1,20 Mrd. EUR

Div. Rendite0,00%

WKNA2AG6H

ISINUS45826J1051

SymbolNTLA

Intellia Therapeutics Aktien News

Sortieren:Datum Meistgelesen

23.04.25PR NewswireLawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

08.04.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA

08.04.25PR NewswireClass Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky

WerbungIntellia Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

07.04.25PR NewswireNTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

31.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

25.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

25.03.25PR NewswireNTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

20.03.25PR NewswireNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit

17.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

04.03.25PR NewswireLevi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

03.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

03.03.25PR NewswireNTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit

28.02.25PR NewswireApril 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLA

26.02.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

24.02.25PR NewswireNTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

18.02.25PR NewswireIntellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA

16.02.25PR NewswireNTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

14.02.25PR NewswireLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders

28.01.25PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA

16.09.22PR NewswireIntellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

09.08.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA

Intellia Therapeutics News

Intellia Therapeutics News: auf dieser Seite finden Sie alle Intellia Therapeutics News und Nachrichten zur Intellia Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Intellia Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Intellia Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.